LEXINGTON, Mass., Nov 03, 2009 (BUSINESS WIRE) ----Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Robert Perez, EVP and COO, will present on Wednesday, November 18, 2009 at 1:45 p.m. Eastern Time at the Lazard Capital Markets 6th Annual Healthcare Conference at the St Regis Hotel in New York City. This presentation will include discussion of the company's business activities, financial outlook, and current news.

A live webcast of the presentation will be accessible through Cubist's website at www.cubist.com in the Investor Relations Conference Calendar section. The webcast will be available on Cubist's website for a period of 30 days after the presentation.

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist began promoting MERREM(R) I.V. (meropenem for injection) in the United States. MERREM is an established broad spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials -- CONSERV(TM)-1 and CONSERV(TM)-2 -- for the reduction of blood loss during cardiac surgery, and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the Company, in collaboration with Alnylam Pharmaceuticals, Inc. (Cambridge, MA), has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology. Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist's web site at www.cubist.com.

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.

AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of companies.

SOURCE: Cubist Pharmaceuticals, Inc.

   Cubist Pharmaceuticals, Inc. 
   Eileen C. McIntyre, 781-860-8533 
   Senior Director, Corporate Communications 
   eileen.mcintyre@cubist.com 
   or 
   Weber Shandwick 
   Tara Murphy, 617-520-7045 
   tara.murphy@webershandwick.com
   

Copyright Business Wire 2009